Biogen Clinical Trial Pipeline — 89 Active Studies

Phase 1: 20, Phase 2: 17, Phase 3: 23, Other: 29

Biogen is the world's leading company in neuroscience drug development, with deep pipelines across Alzheimer's disease, multiple sclerosis, rare neurological conditions, and neuromuscular disease. Leqembi (lecanemab), developed with Eisai, is the first anti-amyloid antibody to receive full FDA approval for early Alzheimer's — validated by the CLARITY AD trial. Their multiple sclerosis portfolio (Tysabri, Tecfidera/Vumerity, natalizumab biosimilars) remains a major franchise supporting pipeline investment. In neuromuscular disease, Spinraza (nusinersen) pioneered SMA treatment. Biogen's rare neurology pipeline includes Skyclarys (omaveloxolone) for Friedreich ataxia — one of the first approved treatments for this orphan disease — and a growing number of gene therapy and antisense oligonucleotide programs targeting devastating neurological conditions.

• Alzheimer's disease / neurodegeneration
• Multiple sclerosis
• Neuromuscular disease (SMA, ALS)
• Rare neurological disorders (Friedreich ataxia)
• Stroke / neuroinflammation

• Leqembi (lecanemab) — anti-amyloid antibody, early Alzheimer's
• Skyclarys (omaveloxolone) — Nrf2 activator, Friedreich ataxia
• Tysabri (natalizumab) — anti-α4 integrin, MS
• Spinraza (nusinersen) — ASO, spinal muscular atrophy
• BIIB059 — BDCA2, systemic lupus erythematosus
• Tofersen — SOD1-ALS antisense oligonucleotide

Biogen's Alzheimer's disease pipeline — Leqembi (lecanemab) combinations, next-generation anti-tau programs, and disease biomarker trials — generates significant new registrations as the field validates anti-amyloid therapy. Their ALS program, including tofersen (Qalsody) for SOD1-ALS, is watched by neurology-focused BD and rare disease teams.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Biogen's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Biogen may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.